JP2024506708A5 - - Google Patents
Info
- Publication number
- JP2024506708A5 JP2024506708A5 JP2023549573A JP2023549573A JP2024506708A5 JP 2024506708 A5 JP2024506708 A5 JP 2024506708A5 JP 2023549573 A JP2023549573 A JP 2023549573A JP 2023549573 A JP2023549573 A JP 2023549573A JP 2024506708 A5 JP2024506708 A5 JP 2024506708A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition according
- chain variable
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110189905 | 2021-02-18 | ||
| CN202110189905.8 | 2021-02-18 | ||
| CN202110506596.2 | 2021-05-10 | ||
| CN202110506596 | 2021-05-10 | ||
| PCT/CN2022/076554 WO2022174775A1 (en) | 2021-02-18 | 2022-02-17 | Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506708A JP2024506708A (ja) | 2024-02-14 |
| JP2024506708A5 true JP2024506708A5 (https=) | 2025-02-27 |
Family
ID=82931194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549573A Pending JP2024506708A (ja) | 2021-02-18 | 2022-02-17 | 特定の乳癌の治療におけるｈｅｒ２を標的とする抗体薬物複合体の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240148894A1 (https=) |
| EP (1) | EP4294455A4 (https=) |
| JP (1) | JP2024506708A (https=) |
| KR (1) | KR20230146526A (https=) |
| CN (1) | CN117460538A (https=) |
| AU (1) | AU2022222937A1 (https=) |
| CA (1) | CA3206798A1 (https=) |
| IL (1) | IL305095A (https=) |
| MX (1) | MX2023009376A (https=) |
| TW (1) | TW202241523A (https=) |
| WO (1) | WO2022174775A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4676543A1 (en) * | 2023-03-10 | 2026-01-14 | Seagen Inc. | Methods of treating cancer using anti-her2 antibody-drug conjugates and her2 kinase inhibitors |
| WO2025054918A1 (en) * | 2023-09-14 | 2025-03-20 | Remegen Co., Ltd. | Methods of treating cancer using anti-her2 antibody-drug conjugates and anti-pd-1 antibodies |
| WO2025054916A1 (en) * | 2023-09-14 | 2025-03-20 | Remegen Co., Ltd. | Methods of treating cervical cancer using anti-her2 antibody-drug conjugates |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101936697B1 (ko) * | 2013-11-19 | 2019-01-10 | 레메젠 리미티드 | 항-her2 항체 및 이의 접합체 |
| TWI727380B (zh) * | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| CA3094194A1 (en) * | 2019-03-26 | 2020-09-26 | Remegen Co., Ltd. | Pharmaceutical formulations of her2 antibody-drug conjugate |
-
2022
- 2022-02-17 WO PCT/CN2022/076554 patent/WO2022174775A1/en not_active Ceased
- 2022-02-17 CA CA3206798A patent/CA3206798A1/en active Pending
- 2022-02-17 EP EP22755548.9A patent/EP4294455A4/en active Pending
- 2022-02-17 IL IL305095A patent/IL305095A/en unknown
- 2022-02-17 JP JP2023549573A patent/JP2024506708A/ja active Pending
- 2022-02-17 AU AU2022222937A patent/AU2022222937A1/en not_active Abandoned
- 2022-02-17 CN CN202280015186.0A patent/CN117460538A/zh active Pending
- 2022-02-17 MX MX2023009376A patent/MX2023009376A/es unknown
- 2022-02-17 KR KR1020237027221A patent/KR20230146526A/ko active Pending
- 2022-02-18 TW TW111106064A patent/TW202241523A/zh unknown
-
2023
- 2023-08-16 US US18/450,966 patent/US20240148894A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12497465B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| CN106459200B (zh) | 抗-egfr抗体及抗体药物偶联物 | |
| JP2024506708A5 (https=) | ||
| KR102115217B1 (ko) | 항-folr1 면역접합체 투여 레지멘 | |
| JP2012522513A5 (https=) | ||
| JP2020509027A5 (https=) | ||
| TW200404005A (en) | Calicheamicin derivative-carrier conjugates | |
| WO2023036137A1 (en) | Process for preparing highly homogenous antibody-drug conjugates for engineered antibodies | |
| JP2015523961A5 (https=) | ||
| CA3093731A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| TW202216212A (zh) | 抗體-藥物結合物之製造方法 | |
| RU2019141270A (ru) | Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| WO2022174775A1 (en) | Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer | |
| JP2025508380A5 (https=) | ||
| JP2024519585A (ja) | 抗ｐ－カドヘリン抗体を含む抗体コンジュゲートおよびその使用 | |
| JP2023546293A5 (https=) | ||
| RU2023123868A (ru) | Применение конъюгата антитело-лекарственное средство, нацеленного на her2, в лечении специфичного рака молочной железы | |
| TW202033217A (zh) | 一種ｃ－Ｍｅｔ ＡＤＣ在製備治療ｃ－Ｍｅｔ激酶抑制劑耐藥的疾病的藥物中的用途 | |
| RU2023134007A (ru) | Применение конъюгата антитело-лекарственное средство в комбинации с ингибитором иммунных контрольных точек в лечении уротелиального рака | |
| RU2023134008A (ru) | Применение конъюгата, нацеленное на her2 антитело - лекарственное средство, в лечении рака молочной железы с низкой экспрессией her2 | |
| CN114845738A (zh) | 使用位点特异性her2抗体-药物缀合物的治疗 | |
| JP2022535276A5 (https=) | ||
| US20260115306A1 (en) | Combination of anti-cdh6 antibody-drug conjugate and vegf inhibitor | |
| JP2024540536A5 (https=) |